个人信息

性别：女

职称：研究员

学历学位：博士

毕业院校：中国药科大学

授课课程

（1）《Medicinal Chemistry》国际学院（2）《药物化学专论》

（3）《有机化学实验》（4）《药物化学》药学院

研究方向/领域

（1）新型激酶抑制剂的发现研究

（2）新型抗结核菌药物发现研究

（3）人工智能药物设计策略研究

近五年成果展示

       重点围绕尚未满足临床需求的恶性肿瘤和肺结核病临床耐药，设计和合成全新的药物先导物。已获得良好生物活性和成药性的先导化合物60余个，主持研发2项1类新药候选分子转化，作为核心骨干参与3项候选新药分子转化。以第一或通讯作者在本专业国际期刊发表SCI论文90余篇（本专业TOP期刊J.Med. Chem. 26篇），参编专著7部。申请发明专利30余项，授权25项。主持国家自然科学基金优秀青年科学基金，国家重点研发计划等项目20多项。入选教育部“长江学者奖励计划”特聘教授、获中国药学会-施维雅药物化学奖、中科院卢嘉锡青年人才奖年、广州市科技进步一等奖和广东省自然科学二等奖。承担本科和研究生6门课程教学工作。获第四届教学创新大赛校级一等奖和省级优秀奖。指导全国药学类大学生实验技能比赛获二等奖，全国医学创新研究医学实验设计比赛铜奖，互联网+国赛银奖。

代表性成果：

1.主持研发了高选择性、高活性的新型TRK抑制剂新一代肺癌靶向药物JND5932，作为第一发明人专利权以总额超过3亿元人民币里程碑合同转让至企业后期开发，目前该候选药物获中美双报临床批件，已进入临床I期研究。

2.主持研发国内首个抑制能量传递的抗肺结核候选药物TB47，作为第一发明人专利权转让至公司开发，TB47被WHO纳入新型抗结核药物研发管线，2024年1月提交SFDA临床申请。

3.主持构建了首个激酶抑制剂共价设计平台kin-Cov，获得国内外同行的广泛认可和使用，为共价抑制剂的设计提供了高效的设计策略。

代表性论文和专著

1.Fang Yang,# Qianmeng Lin,# Xiaojuan Song, Huisi Huang, Xiaojuan Chen, Jianwen Tan, Yun Li, Yang Zhou, Zhengchao Tu, Hongli Du, Zhi-min Zhang, Raquel Ortega, Xiaojing Lin, Adam V. Patterson, Jeff B. Smaill, Yongheng Chen,* and Xiaoyun Lu*. Discovery of 6‑Formylpyridyl Urea Derivatives as Potent Reversible- Covalent Fibroblast Growth Factor Receptor 4 Inhibitors withImproved Anti-Hepatocellular Carcinoma Activity J. Med. Chem. 2024, 67, 2667−2689

2.Zuqin Wang,‡ Jie Wang,‡ Yongjin Wang,‡ Shuang Xiang, Hengliang Zhou, Shukai Song, Xiaojuan Song, Zhengchao Tu, Yang Zhou, Ke Ding, Zhi-Min Zhang,* Zhang Zhang,* and Xiaoyun Lu*. Structure-Based Optimization of the Third Generation Type I Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations. J. Med. Chem. 2023, 66, 12950-12965.

3.Yang Zhou,# Hang Yu,# Anna Constance Vind,# Lulu Kong,# Yiling Liu, Xiaojuan Song, Zhengchao Tu,Caihong Yun, Jeff B. Smaill, Qing-Wen Zhang, Ke Ding, Simon Bekker-Jensen,* and Xiaoyun Lu*. Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov). J. Med. Chem. 2023, 66, 11, 7405-7420.。

4.Qian Li, Tao Zhang , Peiran Song , Linjiang Tong, Fang Feng, Jing Guo , Yang Zhou, Hua Xie, Xiaoyun Lu. Design, Synthesis, and Evaluation of (R)-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor.  J Med Chem. 2023 May 25;66(10):6905-6921

5.Yongjin Wang # , Yang Zhou #, Chaowei Shi #, Jiacong Liu , Guohua Lv, Huisi Huang, Shengrong Li, Liping Duan, Xinyi Zheng, Yue Liu, Haibo Zhou, Yonghua Wang, Zhengqiu Li, Ke Ding,* Pinghua Sun,* Yun Huang,* Xiaoyun Lu,* Zhi-Min Zhang.* A toxin-deformation dependent inhibition mechanism in the T7SS toxin-antitoxin system of Gram-positive bacteria. Nat Commun.2022,13:6434.

6.Chaofan Wang, # Jie Li, # Lingzhi Qu, # Xia Tang, Xiaojuan Song, Fang Yang, Xiaojuan Chen, Qianmeng Lin, Weibin Lin, Yang Zhou, ZhengChao Tu, Yongheng Chen,* Zhang Zhang,* and Xiaoyun Lu*.Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment. J. Med. Chem. 2022, 65, 22, 15140-15164.

7.Fang Yang,# Xiaojuan Chen,# Xiaojuan Song, Raquel Ortega, Xiaojing Lin, Wuqing Deng, Jing Guo, Zhengchao Tu, Adam V. Patterson, Jeff B. Smaill,* Yongheng Chen,* and Xiaoyun Lu*. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors. J. Med. Chem. 2022, 65, 21, 14809-14831.

8.Zuqin Wang#, Jie Wang#, Yongjin Wang#, Shuang Xiang , Xiaojuan Song , Zhengchao Tu , Yang Zhou, Zhi-Min Zhang*, Zhang Zhang*, Ke Ding*, Xiaoyun Lu*.Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance. J. Med. Chem. 2022, 65, 8, 6325-6337.

9.Hao Chen#, Mengzhen Lai #, Tao Zhang, Yuqing Chen, Linjiang Tong, Sujie Zhu , Yang Zhou, Xiaomei Ren, Jian Ding, Hua Xie*, Xiaoyun Lu *, Ke Ding*. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J. Med. Chem. 2022, 65, 9, 6840-6858.

10.Min Shao#, Xiaojuan Chen,# Fang Yang, Xiaojuan Song, Yang Zhou, Qianmeng Lin, Ying Fu, Raquel Ortega, Xiaojing Lin, Zhengchao Tu, Adam V. Patterson, Jeff B. Smaill*, Yongheng Chen*, and Xiaoyun Lu*. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4. J. Med. Chem. 2022, 65, 5113−5133.